At the recent San Antonio Breast Cancer Symposium, two studies stood out to Norah L. Henry, MD, both offering important insights for clinical practice. The first, the PADMA trial, compared endocrine therapy plus palbociclib vs chemotherapy in patients newly diagnosed with high-risk metastatic hormone receptor–positive, HER2-negative breast cancer. The trial found that the combination therapy resulted in over a 10-month improvement in both time to treatment failure and progression-free survival compared with chemotherapy.
The second key study was an exploratory analysis of the TAILORx trial, which examined patients with high 21-gene recurrence scores to assess the benefits of anthracycline-based vs non–anthracycline-based chemotherapy. This analysis found a 5% improvement in distant recurrence–free survival with anthracycline-based chemotherapy, particularly in patients with tumors larger than 2 cm, offering new guidance on chemotherapy selection based on recurrence scores.
Medscape © 2025 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2024: Clinical Impact of Advances in HR+/HER2- Breast Cancer - Medscape - Jan 02, 2025.
Comments